Bone Marrow Disease
13
1
2
6
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
15.4%
2 terminated out of 13 trials
75.0%
-11.5% vs benchmark
8%
1 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (13)
Pacritinib With Aza for Upfront Myelodysplastic Syndrome
Impact of Physical and Occupational Therapy in New BMT Patients
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)
Role of Diffusion MRI in Differentiation of Various Bone Marrow Lesions
A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Tube Feeding in Children Having a Bone Marrow Transplant
OSTEOMICS: Identifying Regulators of Bone Homeostasis
The Effect of Music Therapy on Comfort, Pain and Anxiety
Bone Marrow Adiposity and Fragility Fractures in Postmenopausal Women
Busulfan Concentration in Saliva and Plasma, and Its Relationship With Salivary Changes and Mucositis in the Digestive Tract of Patients Submitted to Hematopoietic Stem Cell Transplantation
Study of Fentanyl-Propofol-EMLA of L.M.X4 Technique for Bone Marrow Aspiration
Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)